Pharmacokinetics and Metabolism of [14C] BMS-690514 in Healthy Male Subjects
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Single dose pharmacokinetics of BMS-690514 and radioactivity in plasma and urine
measured for 10 days post-dose
No
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Switzerland: Swissmedic
CA187-003
NCT00578916
January 2008
January 2008
Name | Location |
---|